MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $105.80 (1.84% downside)

Current Analysts' Coverage Summary for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2015Roth CapitalReiterated RatingBuy$135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015Deutsche BankDowngradeBuy -> Hold$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/21/2014Griffin SecuritiesSet Price Target$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2014Brinson PatrickSet Price Target$98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2014Summer StreetBoost Price TargetBuy$78.00 -> $91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2014MLV & Co.Boost Price TargetBuy$82.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2013Brean CapitalDowngradeBuy -> Hold$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha